Drug MS-553 for diabetic eye swelling with reduced vision
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diabetes (type 1 or type 2) confirmed by standard medical criteria.
- Your eye exam shows diabetic macular edema affecting the center of your macula on an eye scan (sd-OCT).
- Your vision test result is at least 34 letters on the ETDRS eye chart at screening (roughly 20/200 or better).
- You can follow all study instructions and attend all required visits.
- You must agree to prevent pregnancy during the study; women who can become pregnant must have a pregnancy test before starting.
- You either do not plan to get laser/anti-VEGF treatment, or your eye specialist says it’s not needed, and it can be held for at least 3 months after screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
This trial tests an experimental medication (BI 1815368) given as an eye injection for people with diabetic macular edema, a condition where fluid builds up in the center of the retina and blurs vision. The study aims to see if this new treatment can reduce swelling and improve vision.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This early-stage (Phase 1) study tests a new gene therapy to improve vision for adults with diabetic macular edema. It mainly looks at whether the treatment can be safely given and may help your vision over time.
This study tests whether a medication called dapagliflozin, which is usually used for diabetes and heart failure, can help reduce swelling in the retina (diabetic macular edema) and improve vision. It is for people with type 2 diabetes who are already taking insulin and metformin.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.